Overview
Our antiviral drug screening platform enables rapid evaluation of compound efficacy against clinically relevant viruses. The assay is optimized for high-throughput analysis in 96-well formats, providing reliable preclinical data for drug discovery.

Principle

• Viruses are used to infect susceptible cells.

• Test compounds are added either before or after infection.

• Viral replication is measured by inhibition of cytopathic effect (CPE), reduction of viral titers, or through reporter assays.

Applications

• Screening novel antiviral candidates

• Preclinical validation of therapeutic compounds

• Comparative efficacy studies across virus strains

Deliverables from MIV
✔️ Raw and normalized data with curve fitting
✔️ IC₅₀ values for compound efficacy
✔️ Detailed assay report with interpretation
✔️ Technical support for drug development programs

We provide services for a wide range of viruses that are safely handled under Biosafety Level-2 (BSL-2) conditions. Our team ensures precise results with  quality standards, supporting research, vaccine development, and antiviral testing.

We provide services for the following viruses:

• Adenoviruses
• Cytomegalovirus (CMV)
• Dengue virus
• Chikungunya virus
• Herpes simplex virus (HSV-1, HSV-2)
• Influenza viruses (seasonal strains)
• Parainfluenza viruses
• Respiratory syncytial virus (RSV)
• Rubella virus
• Mumps virus
• Measles virus